Gpc3
Clinical Trials Overview
1 trials found
About Gpc3
GPC3 refers to glypican-3-targeted cellular immunotherapy, specifically engineered tumor-infiltrating lymphocytes (TILs) or chimeric antigen receptor T-cells (CAR-T cells) designed to recognize and attack cancer cells expressing the GPC3 protein. This cellular immunotherapy approach involves extracting immune cells from patients, genetically modifying them to target GPC3-positive cancer cells, and reinfusing them to treat advanced solid tumors including colorectal cancer. GPC3-targeted therapies represent a personalized cellular immunotherapy strategy for patients with GPC3-expressing malignancies.
Category
Other Medications
Brand Name
Not yet branded
Mechanism
The engineered immune cells are modified to express receptors that specifically recognize glypican-3 (GPC3), a cell surface proteoglycan that is overexpressed in various solid tumors including some colorectal cancers. Once infused, these modified T-cells bind to GPC3 on tumor cell surfaces, leading to targeted cancer cell destruction through cytotoxic T-cell responses and immune system activation.
1
Total Trials
1
Recruiting
0
Active
0
Completed
40
Total Enrollment
1
Countries
med_trials_active_sites
Recruiting sites
1 countries
NCT04842812
Phase 1
Recruiting
40 patients
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. T...
China